Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME), which provides specialty reference biomarker services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, announced that its corporate name has been officially changed to Pacific Biomarkers, Inc. The name was approved by shareholders and the State of Washington in December 2009. At the present time, the Company is waiting for a pending change in its stock symbol. In the meantime, the shares continue to trade on the OTC Bulletin Board under the symbol "PBME".
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.